Oncology & immuno-oncology
Cell-based assays and CDX, PDX, syngeneic, humanized, orthotopic, or metastatic models for antitumor efficacy and immune-response studies.
Preclinical Pharmacology & Efficacy Studies
In vitro and in vivo pharmacology studies designed to evaluate biological activity, dose response, mechanism-linked endpoints, and therapeutic efficacy in relevant disease models.
Pharmacology studies built around the biological question.
We coordinate study design and execution with partner laboratories selected for the required therapeutic area and model. The program can connect compound supply with in vitro screening, in vivo efficacy, PK/PD, biomarker, and tissue-analysis work.
Study formatsIn vitro, Ex vivo, In vivo
Therapeutic areasOncology, Immune, Metabolic, CNS
Common outputsEfficacy, PK/PD, Biomarkers
Efficacy capabilities across major research areas.
Immunology & inflammation
Pharmacology models and inflammatory, immune, cytokine, histology, and disease-activity readouts aligned to the mechanism of action.
Cardiovascular & cerebrovascular
Disease-model studies for cardiovascular and cerebrovascular pharmacology using project-relevant functional, biomarker, and tissue endpoints.
Neuroscience
Behavioral, neurochemical, electrophysiological, biomarker, and tissue-based endpoints for neurological and neuropsychiatric research programs.
Metabolic disease
Obesity, diabetes, MASH, and related metabolic pharmacology studies with efficacy, exposure, biomarker, and tissue-analysis endpoints.
Translational in vitro systems
Patient-derived organoids, 3D co-culture, organ-on-chip, and other human-relevant systems for screening and translational research.
Common pharmacology and efficacy readouts.
Efficacy
Disease-specific functional outcomes, tumor response, disease activity, or other model-relevant primary endpoints.
Dose response
Dose level, schedule, route, treatment duration, response magnitude, and durability.
PK/PD
Exposure, target engagement, pharmacodynamic response, and efficacy correlation when required.
Biomarkers & tissues
Protocol-defined sample collection, biomarkers, histology, IHC, cytokines, or pathway readouts.
Model availability, study design, endpoints, timelines, and deliverables are confirmed during technical review.
What shapes an efficacy study design.
- Therapeutic area and disease biology
- Compound modality and mechanism of action
- In vitro, ex vivo, or in vivo model selection
- Dose route, schedule, and formulation
- Primary, secondary, and exploratory endpoints
- PK/PD, biomarker, tissue, and reporting requirements
Planning a pharmacology or efficacy study?
Share the compound, therapeutic area, mechanism, preferred model, and intended endpoints. We can review study feasibility and the appropriate partner-laboratory route.Required fields are marked with an asterisk(*).